Stockscreener 앱 받기
74.24
1.97%
-1.49
Lantheus Holdings Inc 주식(LNTH)의 최신 뉴스
William Blair, Jefferies Maintain LNTH Lantheus Holdings March 2026: Outperform Buy - Meyka
Nuclear Medicine (Radiopharmaceuticals) Market Set for Strong Growth at 9.50% CAGR Through 2034: DelveInsight | Lantheus, GE Healthcare, Novartis, Sotera Health and Others - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
CWA Asset Management Group LLC Makes New $1.67 Million Investment in Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lantheus to sell SPECT Business to SHINE Technologies - MSN
LNTH Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges LNTH Investors with Losses to Contact the Firm - The National Law Review
Class Action Announcement for Lantheus Holdings, Inc. Investors - The National Law Review
Form DEF 14A LANTHEUS HOLDINGS For: 20 March - Investing.com
Lantheus Holdings, Inc. ($LNTH) Former CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Lantheus Holdings, Inc. SEC Filing - Stock Titan
Lantheus (NASDAQ: LNTH) 2026 proxy outlines board elections, pay and equity plan - Stock Titan
Lantheus says FDA extended review period for radioactive diagnostic kit - MSN
How Lantheus Holdings Inc. (LNTH) Affects Rotational Strategy Timing - Stock Traders Daily
Lantheus Holdings Inc (LNTH) Trading Down 3.37% on Mar 19 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Connect - ACCESS Newswire
Aug Weekly: Will Lantheus Holdings Inc outperform the market in YEAR2026 Key Highlights & Scalable Portfolio Growth Methods - baoquankhu1.vn
Why Lantheus Holdings Stock Popped by Almost 12% Last Month - AOL.com
Lantheus price target raised to $82 from $80 at Truist - MSN
Lantheus Holdings Q4 2025 earnings preview - MSN
Citizens reiterates Lantheus stock rating after FDA extends review By Investing.com - Investing.com Canada
FDA extends review of Lantheus’ neuroendocrine tumor drug By Investing.com - Investing.com South Africa
Lantheus Holdings Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Lantheus says FDA pushed deadline for reviewing its tumor diagnostic kit application - MSN
Lantheus Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Lantheus stock holds Outperform at William Blair after FDA delay By Investing.com - Investing.com India
Lantheus stock holds Outperform at William Blair after FDA delay - Investing.com
Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application - Asianet Newsable
Lantheus (LNTH) Drug Application Review Extended by FDA - GuruFocus
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs) - Bitget
Jefferies Maintains Buy on Lantheus Holdings (LNTH) Mar 17 2026 - Meyka
US FDA extends review of Lantheus' diagnostic imaging kit by three months - Yahoo Finance
FDA extends review of Lantheus’ neuroendocrine tumor drug - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Jefferies raises Lantheus stock price target on PSMA PET outlook By Investing.com - Investing.com Canada
Lantheus Holdings Inc Stock (ISIN: US5156731020) Faces Pressure as Farallon Sells 3.245 Million Shar - AD HOC NEWS
US FDA extends review of Lantheus’ diagnostic imaging kit by three months - 1470 & 100.3 WMBD
Farallon Capital Management LLC Sells 3,245,000 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
2026-03-15 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation | NDAQ:LNTH | Press Release - Stockhouse
Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Lantheus (NASDAQ:LNTH) Lowered to Buy Rating by Wall Street Zen - MarketBeat
How does Lantheus Holdings Inc compare to its peersLayoff News & Community Consensus Trade Alerts - baoquankhu1.vn
FDA approves Lantheus’ PYLARIFY TruVu for prostate cancer imaging - Investing.com Nigeria
Portolan Capital Management LLC Purchases 42,731 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Secures Two FDA Milestones in Four Days: Lutathera Radioequivalent and PSMA PET Upgrade - Oncodaily
Lantheus Holdings (LNTH) Is Up 5.4% After New PYLARIFY TruVu And LUTATHERA ApprovalsHas The Bull Case Changed? - simplywall.st
Why Lantheus (LNTH) Is Up 5.4% After Dual FDA Wins In Radiopharmaceutical Oncology Expansion - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Lantheus Stock Analysis: 57% Gain Amid Revenue and Margin ConcernsNews and Statistics - IndexBox
Imaging & Diagnostics Stocks Decline After Q4 2025 EarningsNews and Statistics - IndexBox
Q4 Earnings Highlights: Lantheus (NASDAQ:LNTH) Vs The Rest Of The Medical Devices & SuppliesImaging, Diagnostics Stocks - Yahoo Finance
WINTON GROUP Ltd Grows Position in Lantheus Holdings, Inc. $LNTH - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Investors to Inquire about Securities Investigation - ACCESS Newswire
Lantheus at Leerink Conference: Strategic Shifts and Challenges - Investing.com Nigeria
1.75%
1.88%
자본화:
|
볼륨(24시간):